EVOLUTION OF EASI RESPONSE WITH LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO- SEVERE ATOPIC DERMATITIS: POOLED RESULTS FROM TWO PHASE 3 TRIALS (ADVOCATE1 AND ADVOCATE2) AT WEEK 16

被引：0

作者：

Wollenberg, Andreas ^{[1
]}

Warren, Richard B. ^{[2
]}

Silverberg, Jonathan I. ^{[3
]}

Guttman-Yassky, Emma ^{[4
]}

Thaci, Diamant ^{[5
]}

Irvine, Alan D. ^{[6
]}

Gold, Linda Stein ^{[7
]}

Blauvelt, Andrew ^{[8
]}

Simpson, Eric L. ^{[9
]}

Chu, Chia-Yu ^{[10
,11
]}

Liu, Zhuqing T. ^{[12
]}

Lima, Renata Gontijo ^{[12
]}

Pillai, Sreekumar ^{[12
]}

Gil, Esther Garcia ^{[13
]}

Seneschal, Julien ^{[14
,15
]}

机构：

[1] LMU Dept Dermatol & Allergol, Munich, Germany

[2] Univ Manchester, Salford Royal NHS Fdn Trust, Dermatol Ctr, Manchester Nihr Biomed Res Ctr, Manchester, Lancs, England

[3] George Washington Univ, Dept Dermatol, Sch Med, Washington, DC USA

[4] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY USA

[5] Univ Lubeck, Inst & Comprehens Ctr Inflammat Med, Lubeck, Germany

[6] Trinity Coll Dublin, Dept Clin Med, Dublin, Ireland

[7] Henry Ford Hlth Syst, Dermatol Clin Res, Detroit, MI USA

[8] Oregon Med Res Ctr, Portland, OR USA

[9] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR USA

[10] Natl Taiwan Univ Hosp, Dept Dermatol, Taipei, Taiwan

[11] Natl Taiwan Univ, Coll Med, Taipei, Taiwan

[12] Eli Lilly & Co, Indianapolis, IN USA

[13] Almirall SA, Barcelona, Spain

[14] Univ Bordeaux, Dept Dermatol, Bordeaux, France

[15] Hosp St Andre, Natl Reference Ctr Rare Skin Disorders, Dept Dermatol & Pediat Dermatol, Bordeaux, France

来源：

ACTA DERMATO-VENEREOLOGICA | 2023年 / 103卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P10.9

引用

页码：53 / 53

页数：1

共 50 条

[1] Efficacy and safety of lebrikizumab at 16 weeks: pooled analyses from ADvocate1 and ADvocate2 phase III trials in patients with moderate-to-severe atopic dermatitis
Warren, Richard B.
Silverberg, Jonathan I.
Guttman-Yassky, Emma
Thaci, Diamant
Irvine, Alan
Gold, Linda Stein
Blauvelt, Andrew
Simpson, Eric L.
Chu, Chia-Yu
Liu, Zhuqing T.
Lima, Renata Gontijo
Pillai, Sreekumar
Garcia Gil, Esther
Seneschal, Julien
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
[2] Efficacy and Safety of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis: 52-Week Results of Two Randomized, Double-Blinded, Placebo-Controlled Phase 3 Trials (ADvocate1 and ADvocate2)
Marquardt, Tzvetelina
Blauvelt, Andrew
Thyssen, Jacob P.
Guttman-Yassky, Emma
Bieber, Thomas
Serra-Baldrich, Esther
Simpson, Eric
Rosmarin, David
Elmaraghy, Hany
Meskimen, Eric
Natalie, Chitra R.
Liu, Zhuqing
Xu, Chenjia
Pierce, Evangeline
Morgan-Cox, MaryAnn
Silverberg, Jonathan
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 61 - 62
[3] Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized, double-blinded, placebo-controlled phase 3 trials (ADvocate1 and ADvocate2)
Blauvelt, Andrew
Thyssen, Jacob P.
Guttman-Yassky, Emma
Bieber, Thomas
Carrascosa, Jose Manuel
Simpson, Eric
Rosmarin, David
Elmaraghy, Hany
Meskimen, Eric
Natalie, Chitra R.
Liu, Zhuqing
Xu, Chenjia
Pierce, Evangeline
Morgan-Cox, MaryAnn
Silverberg, Jonathan, I
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
[4] Efficacy of Lebrikizumab in Patients With Atopic Dermatitis and Atopic Comorbidities: Pooled Results From Two Phase 3 Monotherapy Randomized, Double-Blind, Placebo-Controlled 16-Week Studies (ADvocate1 and ADvocate2)
Sher, Ellen
Boguniewicz, Mark
Golant, Alexandra
Zhong, Jinglin
Atwater, Amber Reck
Dawson, Zach
Siu, Kimberly
De Bruin-Weller, Marjolein
Carrascosa, Jose-Manuel
Thyssen, Jacob
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB148 - AB148
[5] Efficacy of Lebrikizumab in Patients with Atopic Dermatitis and Atopic Comorbidities: Pooled Results from 2 Phase 3 Monotherapy Randomized, Double-Blind, Placebo-Controlled 16-Week Studies (ADvocate1 and ADvocate2)
Volc, Sebastian
Sher, Ellen R.
Boguniewicz, Mark
Golant, Alexandra K.
de Bruin-Weller, Marjolein S.
Carrascosa, Jose-Manuel
Zhong, Jinglin
Dawson, Zach
Atwater, Amber Reck
Siu, Kimberly
Thyssen, Jacob P.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 79 - 80
[6] Lebrikizumab treatment improves quality of life in patients with moderate-to-severe atopic dermatitis: results from two phase III randomized, double-blinded, placebo-controlled trials (ADvocate1 and ADvocate2)
Lio, Peter
Armstrong, April
Gutermuth, Jan
Nosbaum, Audrey
Sofen, Howard
Casillas, Marta
Pierce, Evangeline
Elmaraghy, Hany
Chen, Sherry
Thyssen, Jacob P.
BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E109 - E110
[7] Efficacy and Safety of Lebrikizumab in moderate to severe atopic Dermatitis: Results of two randomized, double-blind, placebo-controlled phase III Studies (ADvocate1 and ADvocate2) at 52 Weeks
Blauvelt, A.
Thyssen, J. P.
Guttman-Yassky, E.
Bieber, T.
Serra-Baldrich, E.
Simspon, E.
Rosmarin, D.
Diemert, S.
Elmaraghy, H.
Silverberg, J.
ALLERGOLOGIE, 2023, 46 (08) : 530 - 530
[8] Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis
Blauvelt, Andrew
Kircik, Leon
Schlesinger, Todd
Pierce, Evangeline
Burge, Russel
Behling, Michael
Atwater, Amber Reck
Elmaraghy, Hany
Armstrong, April
JOURNAL OF DERMATOLOGICAL TREATMENT, 2025, 36 (01)
[9] Lebrikizumab reduced interference of itch on sleep at 52 weeks in patients with moderate-to- severe atopic dermatitis: pooled analysis of two phase 3 randomized controlled trials
Yosipovitch, Gil
Lio, Peter A.
Rosmarin, David
Legat, Franz J.
Carrascosa, Jose-Manuel
Meskimen, Eric
Casillas, Marta
Pierce, Evangeline
Xu, Chenjia
Zhong, Jinglin
Staender, Sonja
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB61 - AB61
[10] Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized Phase 3 clinical trials
Hebert, Adelaide
Flohr, Carsten
Hong, H. Chih-ho
Irvine, Alan
Pierce, Evangeline
Elmaraghy, Hany
Xu, Wen
Pillai, Sreekumar
Dawson, Zach
Siegfried, Elaine
Weidinger, Stephan
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB159 - AB159

← 1 2 3 4 5 →